TrueWealth Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$943K Buy
7,468
+649
+10% +$85.5K 0.21% 96
2026
Q1
$950K Buy
6,819
+4,700
+222% +$658K 0.24% 80
2025
Q4
$260K Sell
2,119
-459
-18% -$55.8K 0.07% 207
2025
Q3
$286K Buy
2,578
+48
+2% +$5.46K 0.08% 185
2025
Q2
$281K Buy
2,530
+209
+9% +$22.2K 0.08% 182
2025
Q1
$260K Sell
2,321
-380
-14% -$39.2K 0.09% 183
2024
Q4
$249K Sell
2,701
-1,099
-29% -$99K 0.08% 190
2024
Q3
$319K Sell
3,800
-1,120
-23% -$85.5K 0.11% 167
2024
Q2
$338K Buy
4,920
+317
+7% +$21.2K 0.12% 133
2024
Q1
$337K Buy
4,603
+293
+7% +$22.5K 0.13% 133
2023
Q4
$349K Sell
4,310
-42
-1% -$3.27K 0.14% 123
2023
Q3
$326K Buy
4,352
+333
+8% +$25.6K 0.14% 114
2023
Q2
$310K Sell
4,019
-504
-11% -$40.2K 0.13% 125
2023
Q1
$375K Sell
4,523
-121
-3% -$10K 0.16% 99
2022
Q4
$399K Buy
4,644
+776
+20% +$61.5K 0.17% 98
2022
Q3
$239K Buy
3,868
+4
+0.1% +$252 0.11% 137
2022
Q2
$239K Buy
+3,864
New +$239K 0.11% 144

Other funds holding GILD

TrueWealth Advisors's GILD Position: Q2 2026 in Review

TrueWealth Advisors increased its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, buying an estimated $85.5K and bringing the position to 7,468 shares worth $943K. The position accounts for 0.21% of the portfolio, ranked #96.

TrueWealth Advisors first reported a position in GILD in Q2 2022 and has held it in 17 quarters since. The position peaked at $950K in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • TrueWealth Advisors held 7,468 shares of Gilead Sciences worth $943K as of Q2 2026.
  • TrueWealth Advisors bought 649 Gilead Sciences shares in Q2 2026, an estimated $85.5K.
  • Gilead Sciences made up 0.21% of TrueWealth Advisors's portfolio in Q2 2026, its #96 holding.
  • TrueWealth Advisors first reported a position in Gilead Sciences in Q2 2022 and has held it in 17 quarters since.
  • TrueWealth Advisors's Gilead Sciences position peaked at $950K in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on TrueWealth Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.